Title | Creator | Date | ||
---|---|---|---|---|
1 | Neuro-Ophthalmic Manifestations of Pituitary Carcinoma | Emily A. Chang, BS; Ravi Shah, MD; Stacy V. Smith, MD; Ama Sadaka, MD; Juan Ortiz Gomez, MD; Patricia Chevez-Barrios, MD; Andrew G. Lee, MD | 2018-09 | |
2 | Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision | Peter M. K. de Blank, MD, MSCE; Michael J. Fisher, MD; Grant T. Liu, MD; David H. Gutmann, MD, PhD; Robert Listernick, MD; Rosalie E. Ferner, MD; Robert A. Avery, DO, MSCE | 2017-09 | |
3 | Optic Disc Metastasis as the Presenting Sign of Lung Adenocarcinoma | Jonathan A. Micieli, MD, CM; Edward A. Margolin, MD | 2016-12 | |
4 | Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial | Martin W. ten Hove, MD; Deborah I. Friedman, MD; Anil D. Patel, MD; Isabella Irrcher, PhD; Michael Wall, MD; Michael P. McDermott, PhD; for the NORDIC Idiopathic Intracranial Hypertension Study Group | 2016-03 | |
5 | Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial | Kimberly E. Cello, BS; John L. Keltner, MD; Chris A. Johnson, PhD; Michael Wall, MD for the NORDIC Idiopathic Intracranial Hypertension Study Group | 2016-03 |